Mind Medicine (Mind Medicine) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Mind Medicine Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Mind Medicine's annualized Gross Profit for the quarter that ended in Mar. 2024 was $0.00 Mil. Mind Medicine's average Total Assets over the quarter that ended in Mar. 2024 was $200.04 Mil. Therefore, Mind Medicine's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 0.00%.

Mind Medicine Gross-Profit-to-Asset % Historical Data

The historical data trend for Mind Medicine's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mind Medicine Gross-Profit-to-Asset % Chart

Mind Medicine Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Mind Medicine Quarterly Data
	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial													-	-	-	-	-

Competitive Comparison of Mind Medicine's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Mind Medicine's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mind Medicine's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mind Medicine's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Mind Medicine's Gross-Profit-to-Asset % falls into.

Mind Medicine Gross-Profit-to-Asset % Calculation

Mind Medicine's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	0	/	( (169.993	+	124.541)	/ 2 )
	=	0	/	147.267
	=	0.00 %

Mind Medicine's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	0	/	( (124.541	+	275.533)	/ 2 )
	=	0	/	200.037
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Mind Medicine Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Mind Medicine's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mind Medicine (Mind Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (OTCPK:MMCWF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

MNMD:USA MMQ:Germany MMED:Canada

Address

One World Trade Center, Suite 8500, New York, NY, USA, 10007

Website

https://www.mindmed.co

Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.